(Shai Novik) This is a day of celebration for us, and I'm happy for the trust the Israeli capital market provides the company in recent weeks. Continue to invest in and develop companies in order to bring maximum return to investors - and I believe that if we continue the way we started - the results will be excellent."
(Lifetime Achievement Award Accepting the award on behalf of Dr. Frost, Steve Rubin) Dr. Frost wanted to also convey that his career is far from over. "With many career milestones, Opko being the latest and perhaps his best, he is still very much engaged in the industry and is certain there is more to come,"
(Shai Novik) "Opko is already building the distribution channels for the products that it will bring to market in a few years, just as Frost did at Ivax (which Teva acquired for 7.4 billion in 2005). The diagnostics and drugs will be sold by the same sales team to the same doctors," said Prolor president Shai Novik in explaining the synergy between the three businesses.
(Dr. Frost) "We are pleased to complete the acquisition of PROLOR and broaden our portfolio of market-transforming therapies in selected specialty markets," commented Dr. Phillip Frost, OPKO's Chairman and Chief Executive Officer. "With the inclusion of PROLOR's pipeline, OPKO now has four significant products in Phase III clinical development and a robust pipeline of important therapeutic and unique diagnostic products in various stages of development. PROLOR's drug product candidates for growth hormone deficiency, hemophilia, obesity and diabetes, along with its broadly applicable technology platforms and efficient research and development center, are highly valuable assets that complement OPKO's growth strategy."
Sentiment: Strong Buy